Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist ...

China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...

The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

a long-acting beta2-adrenergic agonist (LABA), delivered in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support recommendations put forward by the ...

Inhaled corticosteroids; LABA: Long-acting β 2-agonists; PEF: Peak expiratory flow; Pre-BD: Value measured prebronchodilator; PY: Pack-years; Raw: Airway resistance. In the last 5 years ...

SMART is a treatment where patients use one inhaler that includes both an inhaled corticosteroid (ICS) and a specific long-acting bronchodilator (LABA), called formoterol. This is how one inhaler can ...

Treatment in people aged 12 and over In this group treatment recommendations can be summarised as follows: For patients with minimal symptoms, a 2-in-1 combination inhaler, including the long-acting ...